Abstract
One of the most common forms of neurodegenerative disorders, Alzheimer’s disease poses a great threat to patients all over the globe with about 5.7 million cases estimated by the Alzheimer’s Association Report of 2018. The disorder is a result of β-amyloid deposition in the brain, deteriorating the cognitive ability and learning processes, commonly in geriatric patients. The review significantly elaborates the superiority of nanotechnological formulations over conventional therapeutic strategies, which exhibit numerous side effects, poor pharmacokinetic profiles and limited efficacy, as compared to the nano-medicinal approach. The review recognizes the need to establish an understanding of the transport mechanisms across the blood-brain barrier, prior to the nanoparticle studies, followed by a discussion on various nano-formulations, evidently supported by the outcome of various studies conducted to investigate the drug delivery portfolio of nanomedicines. Furthermore, the review portrays the challenges to overcome in future studies, like nanoparticle fabrication, drug loading capacity, blood residency time, toxicity regime, monitoring long term effects, in-vivo compatibility and production techniques, in order to enable the development of an optimized form of drug delivery process, which would achieve significant heights in the biomedical applications and bring about a revolution in the field of medicine and science.
Keywords: Neurodegenerative disorders, Alzheimer's disease, β-amyloid, cognitive ability, blood-brain barrier, drug delivery process.
Current Drug Targets
Title:Recent Advances in Nanotechnology-Based Drug Delivery Approaches for Alzheimer disease
Volume: 22 Issue: 12
Author(s): Ishnoor Kaur, Arun Kumar*, Tapan Behl and Dhruv Setia
Affiliation:
- Chitkara College of Pharmacy, Chitkara University, Punjab,,India
Keywords: Neurodegenerative disorders, Alzheimer's disease, β-amyloid, cognitive ability, blood-brain barrier, drug delivery process.
Abstract: One of the most common forms of neurodegenerative disorders, Alzheimer’s disease poses a great threat to patients all over the globe with about 5.7 million cases estimated by the Alzheimer’s Association Report of 2018. The disorder is a result of β-amyloid deposition in the brain, deteriorating the cognitive ability and learning processes, commonly in geriatric patients. The review significantly elaborates the superiority of nanotechnological formulations over conventional therapeutic strategies, which exhibit numerous side effects, poor pharmacokinetic profiles and limited efficacy, as compared to the nano-medicinal approach. The review recognizes the need to establish an understanding of the transport mechanisms across the blood-brain barrier, prior to the nanoparticle studies, followed by a discussion on various nano-formulations, evidently supported by the outcome of various studies conducted to investigate the drug delivery portfolio of nanomedicines. Furthermore, the review portrays the challenges to overcome in future studies, like nanoparticle fabrication, drug loading capacity, blood residency time, toxicity regime, monitoring long term effects, in-vivo compatibility and production techniques, in order to enable the development of an optimized form of drug delivery process, which would achieve significant heights in the biomedical applications and bring about a revolution in the field of medicine and science.
Export Options
About this article
Cite this article as:
Kaur Ishnoor , Kumar Arun *, Behl Tapan and Setia Dhruv , Recent Advances in Nanotechnology-Based Drug Delivery Approaches for Alzheimer disease, Current Drug Targets 2021; 22 (12) . https://dx.doi.org/10.2174/1389450122999210104205018
DOI https://dx.doi.org/10.2174/1389450122999210104205018 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phenotypic Screening Strategies for Neurodegenerative Diseases: A Pathway to Discover Novel Drug Candidates and Potential Disease Targets or Mechanisms
CNS & Neurological Disorders - Drug Targets Conference Report
CNS & Neurological Disorders - Drug Targets Current Stage and Future Perspectives for Homology Modeling, Molecular Dynamics Simulations, Machine Learning with Molecular Dynamics, and Quantum Computing for Intrinsically Disordered Proteins and Proteins with Intrinsically Disordered Regions
Current Protein & Peptide Science Small-molecule Modulation of HDAC6 Activity: The Propitious Therapeutic Strategy to Vanquish Neurodegenerative Disorders
Current Medicinal Chemistry Neural Oscillation Disorder in the Hippocampal CA1 Region of Different Alzheimer's Disease Mice
Current Alzheimer Research Current Therapeutic Options for Alzheimers Disease
Current Genomics Neuroprotective and Neurotoxic Implications of α7 Nicotinic Acetylcholine Receptor and Aβ Interaction: Therapeutic Options in Alzheimer's Disease
Current Drug Targets Abeta DNA Vaccination for Alzheimers Disease: Focus on Disease Prevention
CNS & Neurological Disorders - Drug Targets Therapeutic Strategy of Erythropoietin in Neurological Disorders
CNS & Neurological Disorders - Drug Targets <i>Nigella sativa</i> – A Functional Spice From A Pharaoh’s Tomb to Modern Healthcare
The Natural Products Journal From Mice to Macaques – Animal Models of HIV Nervous System Disease
Current HIV Research Stem Cells for Ocular Tissue Engineering and Regeneration
Current Topics in Medicinal Chemistry The Application of Nanomaterials in Cell Autophagy
Current Stem Cell Research & Therapy Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Advancing Glioblastoma Therapy: Promising Research in Precision Medicine
Drug Delivery Letters The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory
Current Pharmaceutical Design Antioxidants as a Potential Preventive and Therapeutic Strategy for Cadmium
Current Drug Targets Cholinesterase Inhibitory Activities of N-Phenylthiazol-2-Amine Derivatives and their Molecular Docking Studies
Medicinal Chemistry Mechanisms of MDMA (Ecstasy)-Induced Oxidative Stress, Mitochondrial Dysfunction, and Organ Damage
Current Pharmaceutical Biotechnology Vitamins and Cognition: A Nutrigenomics Perspective
Current Nutrition & Food Science